CAS 147059-72-1 | 1,8-Naphthyridine-3-carboxylic acid, 7-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo- | CAS Number 147059-72-1

Title	Journal
Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.	Chemical research in toxicology 20170515
MicroRNA-877-5p is involved in the trovafloxacin-induced liver injury.	Toxicology letters 20161130
Cell-Based High-Throughput Screening for Aromatase Inhibitors in the Tox21 10K Library.	Toxicological sciences : an official journal of the Society of Toxicology 20151001
Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related.	Toxicology 20150504
Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.	PloS one 20150101
Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.	The Journal of pharmacology and experimental therapeutics 20140701
Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.	The Journal of pharmacology and experimental therapeutics 20140501
Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction.	Toxicological sciences : an official journal of the Society of Toxicology 20140101
Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.	Toxicological sciences : an official journal of the Society of Toxicology 20140101
Improved fluoroquinolone detection in ELISA through engineering of a broad-specific single-chain variable fragment binding simultaneously to 20 fluoroquinolones.	Analytical and bioanalytical chemistry 20120701
Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection.	Journal of pharmaceutical and biomedical analysis 20120325
Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body.	International journal of nanomedicine 20120101
Plasmid-Mediated Quinolone Resistance; Interactions between Human, Animal, and Environmental Ecologies.	Frontiers in microbiology 20120101
High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis.	Journal of analytical methods in chemistry 20120101
Activity patterns during food provisioning are affected by artificial light in free living great tits (Parus major).	PloS one 20120101
Uncontrolled penile erection and increased sexual desire with intravenous moxifloxacin.	Indian journal of pharmacology 20120101
Genetics of microenvironmental sensitivity of body weight in rainbow trout (Oncorhynchus mykiss) selected for improved growth.	PloS one 20120101
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	PLoS computational biology 20111201
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.	The Journal of antimicrobial chemotherapy 20111101
Calculated carbon-hydrogen bond dissociation enthalpies for predicting oxidative susceptibility of drug substance molecules.	International journal of pharmaceutics 20111014
Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.	Drug safety 20111001
A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.	Korean journal of ophthalmology : KJO 20111001
An insight into the drug resistance profile & mechanism of drug resistance in Neisseria gonorrhoeae.	The Indian journal of medical research 20111001
Prevalence of and Risk Factors for Levofloxacin-Resistant E. coli Isolated from Outpatients with Urinary Tract Infection.	Korean journal of urology 20110801
Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature.	Hepatitis monthly 20110801
Efficacy of serology driven 'test and treat strategy' for eradication of H. pylori in patients with rheumatic disease in the Netherlands.	European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20110701
Hepatic safety of antibiotics used in primary care.	The Journal of antimicrobial chemotherapy 20110701
The binding of triclosan to SmeT, the repressor of the multidrug efflux pump SmeDEF, induces antibiotic resistance in Stenotrophomonas maltophilia.	PLoS pathogens 20110601
In Vitro Activity of 2-methoxy-1,4-naphthoquinone and Stigmasta-7,22-diene-3β-ol from Impatiens balsamina L. against Multiple Antibiotic-Resistant Helicobacter pylori.	Evidence-based complementary and alternative medicine : eCAM 20110101
Hematoma and abscess formation caused by Mycoplasma hominis following cesarean section.	International journal of women's health 20110101
First artificial hybrid of the eel species Anguilla australis and Anguilla anguilla.	BMC developmental biology 20110101
Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.	PloS one 20110101
Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.	International journal of nanomedicine 20110101
Diet-independent remodeling of cellular membranes precedes seasonally changing body temperature in a hibernator.	PloS one 20110101
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.	Clinical ophthalmology (Auckland, N.Z.) 20110101
Variable antibiotic susceptibility patterns among Streptomyces species causing actinomycetoma in man and animals.	Annals of clinical microbiology and antimicrobials 20110101
Institutional review boards - a mixed blessing.	International archives of medicine 20110101
Protective role of α2HS-glycoprotein in HBV-associated liver failure.	International journal of molecular sciences 20110101
Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.	Current pharmaceutical design 20110101
The role of RamA on the development of ciprofloxacin resistance in Salmonella enterica serovar Typhimurium.	PloS one 20110101
MexEF-OprN efflux pump exports the Pseudomonas quinolone signal (PQS) precursor HHQ (4-hydroxy-2-heptylquinoline).	PloS one 20110101
Prescribing medications in patients with decompensated liver cirrhosis.	International journal of hepatology 20110101
Evidence of MexT-independent overexpression of MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa in presence of metabolic stress.	PloS one 20110101
Acquired antibiotic resistance genes: an overview.	Frontiers in microbiology 20110101
Elizabethkingia meningosepticum (Chryseobacterium meningosepticum) Infections in Children.	International journal of pediatrics 20110101
Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients.	Journal of young pharmacists : JYP 20110101
A predictive ligand-based Bayesian model for human drug-induced liver injury.	Drug metabolism and disposition: the biological fate of chemicals 20101201
Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.	Toxicological sciences : an official journal of the Society of Toxicology 20101101
Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction.	Chemico-biological interactions 20101006
Effects of substituents on the NMR features of basic bicyclic ring systems of fluoroquinolone antibiotics and the relationships between NMR chemical shifts, molecular descriptors and drug-likeness parameters.	Acta pharmaceutica (Zagreb, Croatia) 20100901
Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.	Journal of chemotherapy (Florence, Italy) 20100801
Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.	Molecular bioSystems 20100715
Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.	International journal of antimicrobial agents 20100701
Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.	International journal of antimicrobial agents 20100701
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.	Bioorganic & medicinal chemistry letters 20100401
Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance.	Combinatorial chemistry & high throughput screening 20100201
Current approach in the diagnosis and management of posterior uveitis.	Indian journal of ophthalmology 20100101
Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100101
Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.	Chemotherapy 20100101
Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study.	BMC health services research 20100101
Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.	The open microbiology journal 20100101
Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example.	International journal of molecular sciences 20100101
Clinical ethics in African countries and emerging nurse's role in Nigeria.	African journal of medicine and medical sciences 20091201
Efficacy of the quinolones trovafloxacin and grepafloxacin for therapy of experimental tularaemia and plague.	International journal of antimicrobial agents 20091101
Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity.	Toxicological sciences : an official journal of the Society of Toxicology 20091001
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.	Bioorganic & medicinal chemistry 20091001
The use of gastrointestinal intubation studies for controlled release development.	British journal of clinical pharmacology 20090901
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.	Bioorganic & medicinal chemistry 20090801
Spatial memory in the grey mouse lemur (Microcebus murinus).	Animal cognition 20090701
Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.	The Journal of pharmacology and experimental therapeutics 20090701
Spatial and temporal dynamics of lymphocytic choriomeningitis virus in wild rodents, northern Italy.	Emerging infectious diseases 20090701
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.	Toxicology and applied pharmacology 20090615
Shadoo (Sprn) and prion disease incubation time in mice.	Mammalian genome : official journal of the International Mammalian Genome Society 20090601
The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability.	Toxicology and applied pharmacology 20090501
Rocky Mountain spotted fever in dogs, Brazil.	Emerging infectious diseases 20090301
Appeals court rules that Nigerian families can sue Pfizer in US.	BMJ (Clinical research ed.) 20090206
HECTD2 is associated with susceptibility to mouse and human prion disease.	PLoS genetics 20090201
3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity - molecular mechanisms and lessons for pharmacotoxicity.	Human & experimental toxicology 20090201
Emergence of pristinamycin resistance in India.	Indian journal of pharmacology 20090201
Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure.	The Journal of pharmacology and experimental therapeutics 20090101
Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury.	Toxicological sciences : an official journal of the Society of Toxicology 20090101
Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population.	BMC infectious diseases 20090101
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.	Drug safety 20090101
Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA.	Annals of clinical microbiology and antimicrobials 20090101
Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.	International journal of chronic obstructive pulmonary disease 20090101
Inference of antibiotic resistance and virulence among diverse group A Streptococcus strains using emm sequencing and multilocus genotyping methods.	PloS one 20090101
Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.	Clinical ophthalmology (Auckland, N.Z.) 20090101
Ofloxacin induced leucopenia in complicated falciparum malaria: a case report.	Cases journal 20090101
In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa.	Interdisciplinary perspectives on infectious diseases 20090101
Increased incidence of postoperative infections during prophylaxis with cephalothin compared to doxycycline in intestinal surgery.	BMC surgery 20090101
A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.	Bioorganic & medicinal chemistry letters 20081215
Effects of treatment with antimicrobial agents on the human colonic microflora.	Therapeutics and clinical risk management 20081201
Sitafloxacin hydrate for bacterial infections.	Drugs of today (Barcelona, Spain : 1998) 20080701
Methicillin-sensitive Staphylococcus aureus bacteraemia and endocarditis among injection drug users and nonaddicts: host factors, microbiological and serological characteristics.	The Journal of infection 20080401
Plasma protein binding of fluoroquinolones affects antimicrobial activity.	The Journal of antimicrobial chemotherapy 20080301
In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity.	Chemical research in toxicology 20080301
Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells.	Drug metabolism and disposition: the biological fate of chemicals 20080201
Nigerian judge orders arrests of Pfizer officials.	BMJ (Clinical research ed.) 20080105
An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?	Critical care (London, England) 20080101
Levofloxacin-induced delirium with psychotic features.	General hospital psychiatry 20080101
Topoisomerase II inhibition involves characteristic chromosomal expression patterns.	BMC genomics 20080101
Plasmodium knowlesi in humans, macaques and mosquitoes in peninsular Malaysia.	Parasites & vectors 20080101
Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants.	BMC microbiology 20080101
Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance.	PloS one 20080101
Ciprofloxacin induced nightmares in an adult patient.	Indian journal of psychiatry 20080101
Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system.	Bioorganic & medicinal chemistry letters 20071215
History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.	Therapeutics and clinical risk management 20071201
Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.	Therapeutics and clinical risk management 20071201
Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.	Toxicological sciences : an official journal of the Society of Toxicology 20071101
Antimicrobial susceptibility and mechanism of resistance to fluoroquinolones in Staphylococcus intermedius and Staphylococcus schleiferi.	Journal of veterinary pharmacology and therapeutics 20071001
Ocular toxicity of fluoroquinolones.	Clinical & experimental ophthalmology 20070801
Skin and skin structure infections: treatment with newer generation fluoroquinolones.	Therapeutics and clinical risk management 20070601
What led to the Nigerian boycott of the polio vaccination campaign?	PLoS medicine 20070301
Susceptibility of Pediococcus spp. to antimicrobial agents.	Journal of applied microbiology 20070201
Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones.	Antiviral therapy 20070101
Health, human rights, and the conduct of clinical research within oppressed populations.	Globalization and health 20070101
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection.	Critical care (London, England) 20070101
Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones.	European journal of medicinal chemistry 20061201
Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task.	Psychopharmacology 20061201
Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.	Journal of Korean medical science 20061201
Febrile illness associated with Rickettsia conorii infection in dogs from Sicily.	Emerging infectious diseases 20061201
In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.	The Journal of antimicrobial chemotherapy 20060901
Newer fluoroquinolones in the treatment of acute exacerbations of COPD.	International journal of chronic obstructive pulmonary disease 20060901
Dog colonoscopy model for predicting human colon absorption.	Pharmaceutical research 20060701
Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101.	Toxicology in vitro : an international journal published in association with BIBRA 20060401
Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.	Respiratory medicine 20060401
Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils.	The Journal of pharmacology and experimental therapeutics 20060301
Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.	Therapeutics and clinical risk management 20060301
In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus.	International journal of antimicrobial agents 20060201
Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases.	BMC infectious diseases 20060101
Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure.	Microbial drug resistance (Larchmont, N.Y.) 20060101
Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.	BMC infectious diseases 20060101
Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis.	BMC ear, nose, and throat disorders 20060101
Beta-lactam antibiotic-induced release of lipoteichoic acid from Staphylococcus aureus leads to activation of neutrophil granulocytes.	Annals of clinical microbiology and antimicrobials 20060101
Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients.	BMC infectious diseases 20060101
The hepatic transcriptome in human liver disease.	Comparative hepatology 20060101
[Fluoroquinolones and therapy of bacterial meningitis].	Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20060101
Synthesis of new series of 1-Aryl-1,4-dihydro-4-oxo-6-methyl pyridazine-3-carboxylic acid as potential antibacterial agents.	European journal of medicinal chemistry 20051201
Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).	Diagnostic microbiology and infectious disease 20051101
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20050901
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.	Journal of medicinal chemistry 20050811
Telithromycin: the first ketolide antimicrobial.	Clinical therapeutics 20050801
Antimicrobial safety: focus on fluoroquinolones.	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715
Pharmacodynamics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by Streptococcus pneumoniae.	The Journal of antimicrobial chemotherapy 20050701
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.	Journal of pharmaceutical sciences 20050701
Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.	The Journal of antimicrobial chemotherapy 20050401
Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.	International journal of antimicrobial agents 20050401
Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia.	Diagnostic microbiology and infectious disease 20050201
The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].	Journal of clinical gastroenterology 20050101
Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin.	Hepatology (Baltimore, Md.) 20050101
Antitumor activity of trovafloxacin in an animal model.	In vivo (Athens, Greece) 20050101
Do preclinical testing strategies help predict human hepatotoxic potentials?	Toxicologic pathology 20050101
Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.	BMC infectious diseases 20050101
In vitro activities of 11 fluoroquinolones against 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients with special reference to reduced ciprofloxacin susceptibility.	Annals of clinical microbiology and antimicrobials 20050101
In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.	Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 20050101
Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.	Expert review of anti-infective therapy 20041201
In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.	Chemotherapy 20041101
Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.	International journal of antimicrobial agents 20040801
In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.	International journal of antimicrobial agents 20040801
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.	Bioorganic & medicinal chemistry letters 20040607
Comparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolates.	Chemotherapy 20040601
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.	Antimicrobial agents and chemotherapy 20040401
Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine.	Bioorganic & medicinal chemistry letters 20040308
Applications of process analytical technology to crystallization processes.	Advanced drug delivery reviews 20040223
Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.	The Journal of antimicrobial chemotherapy 20040201
Treatment of experimental bacterial keratitis with topical trovafloxacin.	Archives of ophthalmology (Chicago, Ill. : 1960) 20040101
Susceptibility patterns of enterococci causing infections.	The Tohoku journal of experimental medicine 20040101
Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002.	Annals of clinical microbiology and antimicrobials 20040101
Ciprofloxacin-resistant Salmonella enterica Typhimurium and Choleraesuis from pigs to humans, Taiwan.	Emerging infectious diseases 20040101
Quinolone safety and efficacy more important than potency.	Emerging infectious diseases 20040101
Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.	Drug safety 20040101
Telithromycin.	Drugs 20040101
Lack of association between vascular dementia and Chlamydia pneumoniae infection: a case-control study.	BMC neurology 20040101
Fluoroquinolones as chemotherapeutics against mycobacterial infections.	Current pharmaceutical design 20040101
Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit.	Current eye research 20031201
Factors influencing fluoroquinolone resistance.	Emerging infectious diseases 20031201
In vitro fluoroquinolone-resistant mutants of Salmonella enterica serotype Enteritidis: analysis of mechanisms involved in resistance.	International journal of antimicrobial agents 20031101
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.	Respiratory medicine 20031001
Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20031001
Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases.	Journal of chemotherapy (Florence, Italy) 20031001
Levofloxacin and trovafloxacin inhibition of experimental fracture-healing.	Clinical orthopaedics and related research 20030901
The efficacy of trovafloxacin versus ceftriaxone in the treatment of experimental brain abscess/cerebritis in the rat.	Life sciences 20030822
Emergence of fluoroquinolone resistance among Bacteroides species.	The Journal of antimicrobial chemotherapy 20030801
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.	International journal of antimicrobial agents 20030701
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.	Emerging infectious diseases 20030701
Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20030701
Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.	The Journal of antimicrobial chemotherapy 20030601
Immunomodulatory effects of quinolones.	The Lancet. Infectious diseases 20030601
Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.	Respiratory medicine 20030601
Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.	International journal of clinical practice 20030601
Actinobacillus actinomycetemcomitans and Haemophilus aphrophilus in systemic and nonoral infections in Finland.	APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20030601
A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.	Journal of medicinal chemistry 20030508
Adverse drug reactions: implications for the development of fluoroquinolones.	The Journal of antimicrobial chemotherapy 20030501
Maximizing efficacy and reducing the emergence of resistance.	The Journal of antimicrobial chemotherapy 20030501
Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times.	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20030501
In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates.	The Journal of antimicrobial chemotherapy 20030401
In vitro antibacterial activity and pharmacodynamics of new quinolones.	European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20030401
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).	Diagnostic microbiology and infectious disease 20030401
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.	Journal of medicinal chemistry 20030313
Determination of the antibacterial trovafloxacin by differential-pulse adsorptive stripping voltammetry.	Journal of pharmaceutical and biomedical analysis 20030310
[Sensitivity of Haemophilus influenzae isolates in Spain to 17 oral antibiotics].	Enfermedades infecciosas y microbiologia clinica 20030301
Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.	Pediatric pulmonology 20030201
Development and mechanism of fluoroquinolone resistance in Legionella pneumophila.	The Journal of antimicrobial chemotherapy 20030201
Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.	The Journal of toxicological sciences 20030201
Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.	The Journal of antimicrobial chemotherapy 20030101
Maintaining fluoroquinolone class efficacy: review of influencing factors.	Emerging infectious diseases 20030101
Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.	The Journal of laryngology and otology 20030101
Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates.	BMC gastroenterology 20030101
Safety and tolerability of fluoroquinolones.	Clinical cornerstone 20030101
Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.	International journal of antimicrobial agents 20021201
Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20021201
Mechanisms of idiosyncratic drug reactions: the case of felbamate.	Chemico-biological interactions 20021110
Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC).	The Journal of antimicrobial chemotherapy 20021101
In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait.	International journal of antimicrobial agents 20021001
Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.	Diagnostic microbiology and infectious disease 20021001
Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.	Diagnostic microbiology and infectious disease 20021001
Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020901
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020901
Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.	Emerging infectious diseases 20020801
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).	Diagnostic microbiology and infectious disease 20020801
Minimal interaction between gatifloxacin and oxycodone.	Journal of clinical pharmacology 20020801
Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.	International journal of antimicrobial agents 20020801
Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.	International journal of antimicrobial agents 20020701
Antimicrobial-associated acute hepatitis.	Pharmacotherapy 20020601
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20020601
Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).	Diagnostic microbiology and infectious disease 20020601
In vitro photochemical clastogenicity of quinolone antibacterial agents studied by a chromosomal aberration test with light irradiation.	Mutation research 20020527
Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020525
Sentinel surveillance: a reliable way to track antibiotic resistance in communities?	Emerging infectious diseases 20020501
Effect of antibiotics on polymorphonuclear neutrophil apoptosis.	Pharmacotherapy 20020501
A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.	Clinical therapeutics 20020401
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates.	The Journal of antimicrobial chemotherapy 20020301
Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.	Pharmacotherapy 20020301
In vitro assessment of urinary isolates of ampicillin-resistant enterococci.	The Annals of pharmacotherapy 20020201
Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.	International journal of antimicrobial agents 20020201
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.	Diagnostic microbiology and infectious disease 20020201
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.	Journal of chemotherapy (Florence, Italy) 20020201
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.	The Journal of antimicrobial chemotherapy 20020101
Bactericidal mechanism of gatifloxacin compared with other quinolones.	The Journal of antimicrobial chemotherapy 20020101
A critical review of the fluoroquinolones: focus on respiratory infections.	Drugs 20020101
Gatifloxacin: a review of its use in the management of bacterial infections.	Drugs 20020101
Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin.	The Pediatric infectious disease journal 20020101
Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine.	Diagnostic microbiology and infectious disease 20020101
Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae.	Diagnostic microbiology and infectious disease 20020101
Health needs, drug registration and control in less developed countries--the Peruvian case.	Pharmacoepidemiology and drug safety 20020101
[Implantation of transponders at the bottom of the ear in equines].	Berliner und Munchener tierarztliche Wochenschrift 20020101
Possible gatifloxacin-induced fulminant hepatic failure.	The Annals of pharmacotherapy 20020101
Safety of fluoroquinolones: An update.	The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses 20020101
Quinolones and false-positive urine screening for opiates by immunoassay technology.	JAMA 20011226
pH-metric solubility. 3. Dissolution titration template method for solubility determination.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20011201
Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.	The Journal of antimicrobial chemotherapy 20011201
Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.	Chemotherapy 20011201
Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.	Chemotherapy 20011201
Peripheral neuropathy associated with fluoroquinolones.	The Annals of pharmacotherapy 20011201
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.	European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20011201
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].	Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20011201
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].	Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20011201
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.	The Journal of antimicrobial chemotherapy 20011101
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.	The Journal of antimicrobial chemotherapy 20011101
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.	Japanese journal of pharmacology 20011101
Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.	The Journal of antimicrobial chemotherapy 20011001
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.	The Journal of antimicrobial chemotherapy 20011001
High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.	Pediatrics 20011001
Seizures associated with fluoroquinolones.	The Annals of pharmacotherapy 20011001
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.	International journal of antimicrobial agents 20011001
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.	The Journal of infectious diseases 20010915
Drug company sued over research trial in Nigeria.	Lancet (London, England) 20010908
Human research. Nigerian families sue Pfizer, testing the reach of U.S. law.	Science (New York, N.Y.) 20010907
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.	The Journal of antimicrobial chemotherapy 20010901
Future of the quinolones.	Seminars in respiratory infections 20010901
Is more than one quinolone needed in clinical practice?	The Annals of pharmacotherapy 20010901
Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.	International journal of antimicrobial agents 20010901
Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.	Diagnostic microbiology and infectious disease 20010801
Use of broad spectrum antibiotics in six non-university Swiss hospitals.	Swiss medical weekly 20010728
Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.	The Journal of antimicrobial chemotherapy 20010701
Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.	The Journal of antimicrobial chemotherapy 20010701
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.	The Journal of antimicrobial chemotherapy 20010701
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.	International journal of antimicrobial agents 20010701
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.	International journal of antimicrobial agents 20010701
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.	The Journal of antimicrobial chemotherapy 20010701
Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.	American journal of ophthalmology 20010601
Determination of trovafloxacin in human serum by time resolved terbium-sensitised luminescence.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20010601
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.	The Journal of antimicrobial chemotherapy 20010601
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.	International journal of antimicrobial agents 20010601
Effects of low levels of ciprofloxacin on a chemostat model of the human colonic microflora.	Regulatory toxicology and pharmacology : RTP 20010601
Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria.	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20010601
Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.	Journal of chemotherapy (Florence, Italy) 20010601
[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study].	Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20010601
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010515
Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.	The Journal of antimicrobial chemotherapy 20010501
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.	The Journal of antimicrobial chemotherapy 20010501
Acute liver failure.	Current opinion in gastroenterology 20010501
Trovofloxacin for the treatment of chronic granuloma inguinale.	Sexually transmitted infections 20010401
Trovafloxacin hepatotoxicity.	Digestive diseases and sciences 20010401
In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.	European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20010401
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.	Diagnostic microbiology and infectious disease 20010401
In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.	The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20010401
Penicillin-resistant Streptococcus pneumoniae endocarditis: a case report and review.	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010315
Antimicrobial safety and tolerability: differences and dilemmas.	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010315
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.	Current medicinal chemistry 20010301
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.	Saudi medical journal 20010301
Effects of fluoroquinolones on the locomotor activity in rats.	Archives of toxicology 20010301
Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila.	The Journal of antimicrobial chemotherapy 20010201
In vitro activity of new quinolones against Clostridium difficile.	The Journal of antimicrobial chemotherapy 20010201
Guidelines and critical pathways for severe hospital-acquired pneumonia.	Chest 20010201
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.	Journal of clinical pharmacology 20010201
Pfizer accused of testing new drug without ethical approval.	BMJ (Clinical research ed.) 20010127
Nigerian government investigates Pfizer drug trial allegations.	Lancet (London, England) 20010113
Bactericidal assays for fluoroquinolones.	Methods in molecular biology (Clifton, N.J.) 20010101
In vitro development of resistance to three quinolones in Streptococcus pneumoniae.	Chemotherapy 20010101
Measurement of the bactericidal activity of fluoroquinolones against Streptococcus pneumoniae using the bactericidal index method.	International journal of antimicrobial agents 20010101
Antibiotic side effects.	The Medical clinics of North America 20010101
Multifocal Staphylococcus aureus infection originating from the sacroiliac joint in a patient with rheumatoid arthritis.	The Journal of rheumatology 20010101
Trovafloxacin-associated leukopenia.	The Annals of pharmacotherapy 20010101
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.	Microbial drug resistance (Larchmont, N.Y.) 20010101
Telithromycin.	Drugs 20010101
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.	Diagnostic microbiology and infectious disease 20010101
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.	Diagnostic microbiology and infectious disease 20010101
Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae.	BMC microbiology 20010101
Serious liver injury. Leading reason for drug removals, restrictions.	FDA consumer 20010101
Experimental intravitreal application of trovafloxacin in rabbits.	Ophthalmic research 20010101
History of quinolones and their side effects.	Chemotherapy 20010101
Comparison of side effects of levofloxacin versus other fluoroquinolones.	Chemotherapy 20010101
Latest industry information on the safety profile of levofloxacin in Japan.	Chemotherapy 20010101
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.	Chemotherapy 20010101
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.	Diagnostic microbiology and infectious disease 20010101
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.	Cardiovascular drugs and therapy 20010101
Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico.	Scandinavian journal of infectious diseases 20010101
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.	Antimicrobial agents and chemotherapy 20001001
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.	Antimicrobial agents and chemotherapy 20001001
In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.	Antimicrobial agents and chemotherapy 20000901
Effects of trovafloxacin on the IL-1-dependent activation of E-selectin in human endothelial cells in vitro.	Immunopharmacology 20000601
Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin.	Pharmacotherapy 20000501
Trovafloxacin-induced weakness due to a demyelinating polyneuropathy.	Southern medical journal 20000501
Trovafloxacin-induced acute hepatitis.	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20000201
Double-blind comparison of trovafloxacin and doxycycline in the treatment of uncomplicated Chlamydial urethritis and cervicitis. Trovafloxacin Chlamydial Urethritis/Cervicitis Study Group.	Sexually transmitted diseases 19991001
Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin.	Antimicrobial agents and chemotherapy 19990701
The 2-pyridone antibacterial agents: 8-position modifications.	Current pharmaceutical design 19990701
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.	Antimicrobial agents and chemotherapy 19990501
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.	European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19980601
In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.	The Journal of antimicrobial chemotherapy 19971201
In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.	The Journal of antimicrobial chemotherapy 19970601
Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.	Antimicrobial agents and chemotherapy 19970501
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.	The Journal of antimicrobial chemotherapy 19970401
Trovafloxacin is active against Toxoplasma gondii.	Antimicrobial agents and chemotherapy 19960801

Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.

The Journal of pharmacology and experimental therapeutics 20140701

Trovafloxacin potentiation of lipopolysaccharide-induced tumor necrosis factor release from RAW 264.7 cells requires extracellular signal-regulated kinase and c-Jun N-Terminal Kinase.

The Journal of pharmacology and experimental therapeutics 20140501

Molecular mechanisms of hepatocellular apoptosis induced by trovafloxacin-tumor necrosis factor-alpha interaction.

Toxicological sciences : an official journal of the Society of Toxicology 20140101

Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.

Toxicological sciences : an official journal of the Society of Toxicology 20140101

Improved fluoroquinolone detection in ELISA through engineering of a broad-specific single-chain variable fragment binding simultaneously to 20 fluoroquinolones.

Analytical and bioanalytical chemistry 20120701

Determination of trovafloxacin and marbofloxacin in sheep plasma samples by HPLC using UV detection.

Journal of pharmaceutical and biomedical analysis 20120325

Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body.

International journal of nanomedicine 20120101

Plasmid-Mediated Quinolone Resistance; Interactions between Human, Animal, and Environmental Ecologies.

Frontiers in microbiology 20120101

High-performance liquid chromatography assay for moxifloxacin in brain tissue and plasma: validation in a pharmacokinetic study in a murine model of cerebral listeriosis.

Journal of analytical methods in chemistry 20120101

Activity patterns during food provisioning are affected by artificial light in free living great tits (Parus major).

PloS one 20120101

Uncontrolled penile erection and increased sexual desire with intravenous moxifloxacin.

Indian journal of pharmacology 20120101

Genetics of microenvironmental sensitivity of body weight in rainbow trout (Oncorhynchus mykiss) selected for improved growth.

PloS one 20120101

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.

The Journal of antimicrobial chemotherapy 20111101

Calculated carbon-hydrogen bond dissociation enthalpies for predicting oxidative susceptibility of drug substance molecules.

International journal of pharmaceutics 20111014

Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

Drug safety 20111001

A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.

Korean journal of ophthalmology : KJO 20111001

An insight into the drug resistance profile & mechanism of drug resistance in Neisseria gonorrhoeae.

The Indian journal of medical research 20111001

Prevalence of and Risk Factors for Levofloxacin-Resistant E. coli Isolated from Outpatients with Urinary Tract Infection.

Korean journal of urology 20110801

Liver injury induced by high-dose methylprednisolone therapy: a case report and brief review of the literature.

Hepatitis monthly 20110801

Efficacy of serology driven 'test and treat strategy' for eradication of H. pylori in patients with rheumatic disease in the Netherlands.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20110701

Hepatic safety of antibiotics used in primary care.

The Journal of antimicrobial chemotherapy 20110701

The binding of triclosan to SmeT, the repressor of the multidrug efflux pump SmeDEF, induces antibiotic resistance in Stenotrophomonas maltophilia.

PLoS pathogens 20110601

In Vitro Activity of 2-methoxy-1,4-naphthoquinone and Stigmasta-7,22-diene-3β-ol from Impatiens balsamina L. against Multiple Antibiotic-Resistant Helicobacter pylori.

Evidence-based complementary and alternative medicine : eCAM 20110101

Hematoma and abscess formation caused by Mycoplasma hominis following cesarean section.

International journal of women's health 20110101

First artificial hybrid of the eel species Anguilla australis and Anguilla anguilla.

BMC developmental biology 20110101

Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.

PloS one 20110101

Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles.

International journal of nanomedicine 20110101

Diet-independent remodeling of cellular membranes precedes seasonally changing body temperature in a hibernator.

PloS one 20110101

Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.

Clinical ophthalmology (Auckland, N.Z.) 20110101

Variable antibiotic susceptibility patterns among Streptomyces species causing actinomycetoma in man and animals.

Annals of clinical microbiology and antimicrobials 20110101

Institutional review boards - a mixed blessing.

International archives of medicine 20110101

Protective role of α2HS-glycoprotein in HBV-associated liver failure.

International journal of molecular sciences 20110101

Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.

Current pharmaceutical design 20110101

The role of RamA on the development of ciprofloxacin resistance in Salmonella enterica serovar Typhimurium.

PloS one 20110101

MexEF-OprN efflux pump exports the Pseudomonas quinolone signal (PQS) precursor HHQ (4-hydroxy-2-heptylquinoline).

PloS one 20110101

Prescribing medications in patients with decompensated liver cirrhosis.

International journal of hepatology 20110101

Evidence of MexT-independent overexpression of MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa in presence of metabolic stress.

PloS one 20110101

Acquired antibiotic resistance genes: an overview.

Frontiers in microbiology 20110101

Elizabethkingia meningosepticum (Chryseobacterium meningosepticum) Infections in Children.

International journal of pediatrics 20110101

Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients.

Journal of young pharmacists : JYP 20110101

A predictive ligand-based Bayesian model for human drug-induced liver injury.

Drug metabolism and disposition: the biological fate of chemicals 20101201

Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Toxicological sciences : an official journal of the Society of Toxicology 20101101

Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction.

Chemico-biological interactions 20101006

Effects of substituents on the NMR features of basic bicyclic ring systems of fluoroquinolone antibiotics and the relationships between NMR chemical shifts, molecular descriptors and drug-likeness parameters.

Acta pharmaceutica (Zagreb, Croatia) 20100901

Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.

Journal of chemotherapy (Florence, Italy) 20100801

Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.

Molecular bioSystems 20100715

Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.

International journal of antimicrobial agents 20100701

Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.

International journal of antimicrobial agents 20100701

Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.

Bioorganic & medicinal chemistry letters 20100401

Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance.

Combinatorial chemistry & high throughput screening 20100201

Current approach in the diagnosis and management of posterior uveitis.

Indian journal of ophthalmology 20100101

Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100101

Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.

Chemotherapy 20100101

Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study.

BMC health services research 20100101

Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

The open microbiology journal 20100101

Comparison of TNFα to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example.

International journal of molecular sciences 20100101

Clinical ethics in African countries and emerging nurse's role in Nigeria.

African journal of medicine and medical sciences 20091201

Efficacy of the quinolones trovafloxacin and grepafloxacin for therapy of experimental tularaemia and plague.

International journal of antimicrobial agents 20091101

Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity.

Toxicological sciences : an official journal of the Society of Toxicology 20091001

Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.

Bioorganic & medicinal chemistry 20091001

The use of gastrointestinal intubation studies for controlled release development.

British journal of clinical pharmacology 20090901

7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.

Bioorganic & medicinal chemistry 20090801

Spatial memory in the grey mouse lemur (Microcebus murinus).

Animal cognition 20090701

Trovafloxacin enhances the inflammatory response to a Gram-negative or a Gram-positive bacterial stimulus, resulting in neutrophil-dependent liver injury in mice.

The Journal of pharmacology and experimental therapeutics 20090701

Spatial and temporal dynamics of lymphocytic choriomeningitis virus in wild rodents, northern Italy.

Emerging infectious diseases 20090701

Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.

Toxicology and applied pharmacology 20090615

Shadoo (Sprn) and prion disease incubation time in mice.

Mammalian genome : official journal of the International Mammalian Genome Society 20090601

The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability.

Toxicology and applied pharmacology 20090501

Rocky Mountain spotted fever in dogs, Brazil.

Emerging infectious diseases 20090301

Appeals court rules that Nigerian families can sue Pfizer in US.

BMJ (Clinical research ed.) 20090206

HECTD2 is associated with susceptibility to mouse and human prion disease.

PLoS genetics 20090201

3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity - molecular mechanisms and lessons for pharmacotoxicity.

Human & experimental toxicology 20090201

Emergence of pristinamycin resistance in India.

Indian journal of pharmacology 20090201

Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure.

The Journal of pharmacology and experimental therapeutics 20090101

Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury.

Toxicological sciences : an official journal of the Society of Toxicology 20090101

Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population.

BMC infectious diseases 20090101

Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Drug safety 20090101

Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA.

Annals of clinical microbiology and antimicrobials 20090101

Gemifloxacin use in the treatment of acute bacterial exacerbation of chronic bronchitis.

International journal of chronic obstructive pulmonary disease 20090101

Inference of antibiotic resistance and virulence among diverse group A Streptococcus strains using emm sequencing and multilocus genotyping methods.

PloS one 20090101

Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Clinical ophthalmology (Auckland, N.Z.) 20090101

Ofloxacin induced leucopenia in complicated falciparum malaria: a case report.

Cases journal 20090101

In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa.

Interdisciplinary perspectives on infectious diseases 20090101

Increased incidence of postoperative infections during prophylaxis with cephalothin compared to doxycycline in intestinal surgery.

BMC surgery 20090101

A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives.

Bioorganic & medicinal chemistry letters 20081215

Effects of treatment with antimicrobial agents on the human colonic microflora.

Therapeutics and clinical risk management 20081201

Sitafloxacin hydrate for bacterial infections.

Drugs of today (Barcelona, Spain : 1998) 20080701

Methicillin-sensitive Staphylococcus aureus bacteraemia and endocarditis among injection drug users and nonaddicts: host factors, microbiological and serological characteristics.

The Journal of infection 20080401

Plasma protein binding of fluoroquinolones affects antimicrobial activity.

The Journal of antimicrobial chemotherapy 20080301

In vitro metabolism of a model cyclopropylamine to reactive intermediate: insights into trovafloxacin-induced hepatotoxicity.

Chemical research in toxicology 20080301

Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells.

Drug metabolism and disposition: the biological fate of chemicals 20080201

Nigerian judge orders arrests of Pfizer officials.

BMJ (Clinical research ed.) 20080105

An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?

Critical care (London, England) 20080101

Levofloxacin-induced delirium with psychotic features.

General hospital psychiatry 20080101

Topoisomerase II inhibition involves characteristic chromosomal expression patterns.

BMC genomics 20080101

Plasmodium knowlesi in humans, macaques and mosquitoes in peninsular Malaysia.

Parasites & vectors 20080101

Predictive analysis of transmissible quinolone resistance indicates Stenotrophomonas maltophilia as a potential source of a novel family of Qnr determinants.

BMC microbiology 20080101

Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance.

PloS one 20080101

Ciprofloxacin induced nightmares in an adult patient.

Indian journal of psychiatry 20080101

Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system.

Bioorganic & medicinal chemistry letters 20071215

History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.

Therapeutics and clinical risk management 20071201

Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.

Therapeutics and clinical risk management 20071201

Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.

Toxicological sciences : an official journal of the Society of Toxicology 20071101

Antimicrobial susceptibility and mechanism of resistance to fluoroquinolones in Staphylococcus intermedius and Staphylococcus schleiferi.

Journal of veterinary pharmacology and therapeutics 20071001

Ocular toxicity of fluoroquinolones.

Clinical & experimental ophthalmology 20070801

Skin and skin structure infections: treatment with newer generation fluoroquinolones.

Therapeutics and clinical risk management 20070601

What led to the Nigerian boycott of the polio vaccination campaign?

PLoS medicine 20070301

Susceptibility of Pediococcus spp. to antimicrobial agents.

Journal of applied microbiology 20070201

Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones.

Antiviral therapy 20070101

Health, human rights, and the conduct of clinical research within oppressed populations.

Globalization and health 20070101

Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection.

Critical care (London, England) 20070101

Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones.

European journal of medicinal chemistry 20061201

Impaired performance of alpha7 nicotinic receptor knockout mice in the five-choice serial reaction time task.

Psychopharmacology 20061201

Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.

Journal of Korean medical science 20061201

Febrile illness associated with Rickettsia conorii infection in dogs from Sicily.

Emerging infectious diseases 20061201

In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.

The Journal of antimicrobial chemotherapy 20060901

Newer fluoroquinolones in the treatment of acute exacerbations of COPD.

International journal of chronic obstructive pulmonary disease 20060901

Dog colonoscopy model for predicting human colon absorption.

Pharmaceutical research 20060701

Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101.

Toxicology in vitro : an international journal published in association with BIBRA 20060401

Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.

Respiratory medicine 20060401

Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils.

The Journal of pharmacology and experimental therapeutics 20060301

Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia.

Therapeutics and clinical risk management 20060301

In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus.

International journal of antimicrobial agents 20060201

Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases.

BMC infectious diseases 20060101

Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure.

Microbial drug resistance (Larchmont, N.Y.) 20060101

Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.

BMC infectious diseases 20060101

Eradication of common pathogens at days 2, 3 and 4 of moxifloxacin therapy in patients with acute bacterial sinusitis.

BMC ear, nose, and throat disorders 20060101

Beta-lactam antibiotic-induced release of lipoteichoic acid from Staphylococcus aureus leads to activation of neutrophil granulocytes.

Annals of clinical microbiology and antimicrobials 20060101

Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients.

BMC infectious diseases 20060101

The hepatic transcriptome in human liver disease.

Comparative hepatology 20060101

[Fluoroquinolones and therapy of bacterial meningitis].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20060101

Synthesis of new series of 1-Aryl-1,4-dihydro-4-oxo-6-methyl pyridazine-3-carboxylic acid as potential antibacterial agents.

European journal of medicinal chemistry 20051201

Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).

Diagnostic microbiology and infectious disease 20051101

The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20050901

A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.

Journal of medicinal chemistry 20050811

Telithromycin: the first ketolide antimicrobial.

Clinical therapeutics 20050801

Antimicrobial safety: focus on fluoroquinolones.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715

Pharmacodynamics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by Streptococcus pneumoniae.

The Journal of antimicrobial chemotherapy 20050701

Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.

Journal of pharmaceutical sciences 20050701

Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.

The Journal of antimicrobial chemotherapy 20050401

Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.

International journal of antimicrobial agents 20050401

Effect of cirrhosis on antibiotic efficacy in a rat model of pneumococcal pneumonia.

Diagnostic microbiology and infectious disease 20050201

The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].

Journal of clinical gastroenterology 20050101

Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin.

Hepatology (Baltimore, Md.) 20050101

Antitumor activity of trovafloxacin in an animal model.

In vivo (Athens, Greece) 20050101

Do preclinical testing strategies help predict human hepatotoxic potentials?

Toxicologic pathology 20050101

Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.

BMC infectious diseases 20050101

In vitro activities of 11 fluoroquinolones against 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients with special reference to reduced ciprofloxacin susceptibility.

Annals of clinical microbiology and antimicrobials 20050101

In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.

Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 20050101

Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.

Expert review of anti-infective therapy 20041201

In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.

Chemotherapy 20041101

Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.

International journal of antimicrobial agents 20040801

In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.

International journal of antimicrobial agents 20040801

Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.

Bioorganic & medicinal chemistry letters 20040607

Comparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolates.

Chemotherapy 20040601

Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Antimicrobial agents and chemotherapy 20040401

Syntheses and biological evaluation of new fluoroquinolone antibacterials containing chiral oxiimino pyrrolidine.

Bioorganic & medicinal chemistry letters 20040308

Applications of process analytical technology to crystallization processes.

Advanced drug delivery reviews 20040223

Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.

The Journal of antimicrobial chemotherapy 20040201

Treatment of experimental bacterial keratitis with topical trovafloxacin.

Archives of ophthalmology (Chicago, Ill. : 1960) 20040101

Susceptibility patterns of enterococci causing infections.

The Tohoku journal of experimental medicine 20040101

Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002.

Annals of clinical microbiology and antimicrobials 20040101

Ciprofloxacin-resistant Salmonella enterica Typhimurium and Choleraesuis from pigs to humans, Taiwan.

Emerging infectious diseases 20040101

Quinolone safety and efficacy more important than potency.

Emerging infectious diseases 20040101

Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.

Drug safety 20040101

Telithromycin.

Drugs 20040101

Lack of association between vascular dementia and Chlamydia pneumoniae infection: a case-control study.

BMC neurology 20040101

Fluoroquinolones as chemotherapeutics against mycobacterial infections.

Current pharmaceutical design 20040101

Ocular toxicity of intravitreal trovafloxacin in the pigmented rabbit.

Current eye research 20031201

Factors influencing fluoroquinolone resistance.

Emerging infectious diseases 20031201

In vitro fluoroquinolone-resistant mutants of Salmonella enterica serotype Enteritidis: analysis of mechanisms involved in resistance.

International journal of antimicrobial agents 20031101

Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.

Respiratory medicine 20031001

Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20031001

Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases.

Journal of chemotherapy (Florence, Italy) 20031001

Levofloxacin and trovafloxacin inhibition of experimental fracture-healing.

Clinical orthopaedics and related research 20030901

The efficacy of trovafloxacin versus ceftriaxone in the treatment of experimental brain abscess/cerebritis in the rat.

Life sciences 20030822

Emergence of fluoroquinolone resistance among Bacteroides species.

The Journal of antimicrobial chemotherapy 20030801

In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.

International journal of antimicrobial agents 20030701

Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.

Emerging infectious diseases 20030701

Serum bactericidal activity of trovafloxacin, in combination with cefepime or amikacin, in healthy volunteers.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20030701

Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.

The Journal of antimicrobial chemotherapy 20030601

Immunomodulatory effects of quinolones.

The Lancet. Infectious diseases 20030601

Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.

Respiratory medicine 20030601

Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.

International journal of clinical practice 20030601

Actinobacillus actinomycetemcomitans and Haemophilus aphrophilus in systemic and nonoral infections in Finland.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20030601

A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.

Journal of medicinal chemistry 20030508

Adverse drug reactions: implications for the development of fluoroquinolones.

The Journal of antimicrobial chemotherapy 20030501

Maximizing efficacy and reducing the emergence of resistance.

The Journal of antimicrobial chemotherapy 20030501

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20030501

In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates.

The Journal of antimicrobial chemotherapy 20030401

In vitro antibacterial activity and pharmacodynamics of new quinolones.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20030401

Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).

Diagnostic microbiology and infectious disease 20030401

Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.

Journal of medicinal chemistry 20030313

Determination of the antibacterial trovafloxacin by differential-pulse adsorptive stripping voltammetry.

Journal of pharmaceutical and biomedical analysis 20030310

[Sensitivity of Haemophilus influenzae isolates in Spain to 17 oral antibiotics].

Enfermedades infecciosas y microbiologia clinica 20030301

Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.

Pediatric pulmonology 20030201

Development and mechanism of fluoroquinolone resistance in Legionella pneumophila.

The Journal of antimicrobial chemotherapy 20030201

Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.

The Journal of toxicological sciences 20030201

Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.

The Journal of antimicrobial chemotherapy 20030101

Maintaining fluoroquinolone class efficacy: review of influencing factors.

Emerging infectious diseases 20030101

Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.

The Journal of laryngology and otology 20030101

Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates.

BMC gastroenterology 20030101

Safety and tolerability of fluoroquinolones.

Clinical cornerstone 20030101

Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.

International journal of antimicrobial agents 20021201

Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20021201

Mechanisms of idiosyncratic drug reactions: the case of felbamate.

Chemico-biological interactions 20021110

Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC).

The Journal of antimicrobial chemotherapy 20021101

In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait.

International journal of antimicrobial agents 20021001

Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.

Diagnostic microbiology and infectious disease 20021001

Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.

Diagnostic microbiology and infectious disease 20021001

Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020901

Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020901

Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.

Emerging infectious diseases 20020801

In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).

Diagnostic microbiology and infectious disease 20020801

Minimal interaction between gatifloxacin and oxycodone.

Journal of clinical pharmacology 20020801

Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.

International journal of antimicrobial agents 20020801

Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.

International journal of antimicrobial agents 20020701

Antimicrobial-associated acute hepatitis.

Pharmacotherapy 20020601

Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20020601

Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).

Diagnostic microbiology and infectious disease 20020601

In vitro photochemical clastogenicity of quinolone antibacterial agents studied by a chromosomal aberration test with light irradiation.

Mutation research 20020527

Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020525

Sentinel surveillance: a reliable way to track antibiotic resistance in communities?

Emerging infectious diseases 20020501

Effect of antibiotics on polymorphonuclear neutrophil apoptosis.

Pharmacotherapy 20020501

A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.

Clinical therapeutics 20020401

Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates.

The Journal of antimicrobial chemotherapy 20020301

Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.

Pharmacotherapy 20020301

In vitro assessment of urinary isolates of ampicillin-resistant enterococci.

The Annals of pharmacotherapy 20020201

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.

International journal of antimicrobial agents 20020201

In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.

Diagnostic microbiology and infectious disease 20020201

Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.

Journal of chemotherapy (Florence, Italy) 20020201

Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.

The Journal of antimicrobial chemotherapy 20020101

Bactericidal mechanism of gatifloxacin compared with other quinolones.

The Journal of antimicrobial chemotherapy 20020101

A critical review of the fluoroquinolones: focus on respiratory infections.

Drugs 20020101

Gatifloxacin: a review of its use in the management of bacterial infections.

Drugs 20020101

Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin.

The Pediatric infectious disease journal 20020101

Susceptibility of human isolates of Salmonella typhimurium DT 104 to antimicrobial agents used in human and veterinary medicine.

Diagnostic microbiology and infectious disease 20020101

Influence of CO(2) incubation on quinolone activity against Streptococcus pneumoniae and Haemophilus influenzae.

Diagnostic microbiology and infectious disease 20020101

Health needs, drug registration and control in less developed countries--the Peruvian case.

Pharmacoepidemiology and drug safety 20020101

[Implantation of transponders at the bottom of the ear in equines].

Berliner und Munchener tierarztliche Wochenschrift 20020101

Possible gatifloxacin-induced fulminant hepatic failure.

The Annals of pharmacotherapy 20020101

Safety of fluoroquinolones: An update.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses 20020101

Quinolones and false-positive urine screening for opiates by immunoassay technology.

JAMA 20011226

pH-metric solubility. 3. Dissolution titration template method for solubility determination.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20011201

Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.

The Journal of antimicrobial chemotherapy 20011201

Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.

Chemotherapy 20011201

Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.

Chemotherapy 20011201

Peripheral neuropathy associated with fluoroquinolones.

The Annals of pharmacotherapy 20011201

Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20011201

[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20011201

[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20011201

Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.

The Journal of antimicrobial chemotherapy 20011101

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.

The Journal of antimicrobial chemotherapy 20011101

A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.

Japanese journal of pharmacology 20011101

Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones.

The Journal of antimicrobial chemotherapy 20011001

Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.

The Journal of antimicrobial chemotherapy 20011001

High rates of multiple antibiotic resistance in Streptococcus pneumoniae from healthy children living in isolated rural communities: association with cephalosporin use and intrafamilial transmission.

Pediatrics 20011001

Seizures associated with fluoroquinolones.

The Annals of pharmacotherapy 20011001

Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.

International journal of antimicrobial agents 20011001

Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.

The Journal of infectious diseases 20010915

Drug company sued over research trial in Nigeria.

Lancet (London, England) 20010908

Human research. Nigerian families sue Pfizer, testing the reach of U.S. law.

Science (New York, N.Y.) 20010907

Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.

The Journal of antimicrobial chemotherapy 20010901

Future of the quinolones.

Seminars in respiratory infections 20010901

Is more than one quinolone needed in clinical practice?

The Annals of pharmacotherapy 20010901

Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.

International journal of antimicrobial agents 20010901

Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.

Diagnostic microbiology and infectious disease 20010801

Use of broad spectrum antibiotics in six non-university Swiss hospitals.

Swiss medical weekly 20010728

Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.

The Journal of antimicrobial chemotherapy 20010701

Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.

The Journal of antimicrobial chemotherapy 20010701

Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.

The Journal of antimicrobial chemotherapy 20010701

Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.

International journal of antimicrobial agents 20010701

Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.

International journal of antimicrobial agents 20010701

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.

The Journal of antimicrobial chemotherapy 20010701

Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.

American journal of ophthalmology 20010601

Determination of trovafloxacin in human serum by time resolved terbium-sensitised luminescence.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20010601

Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.

The Journal of antimicrobial chemotherapy 20010601

Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.

International journal of antimicrobial agents 20010601

Effects of low levels of ciprofloxacin on a chemostat model of the human colonic microflora.

Regulatory toxicology and pharmacology : RTP 20010601

Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20010601

Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.

Journal of chemotherapy (Florence, Italy) 20010601

[Are the antimicrobials used in community-acquired respiratory infection useful for preventing transmission of meningococcal disease? In vitro study].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20010601

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010515

Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae.

The Journal of antimicrobial chemotherapy 20010501

Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.

The Journal of antimicrobial chemotherapy 20010501

Acute liver failure.

Current opinion in gastroenterology 20010501

Trovofloxacin for the treatment of chronic granuloma inguinale.

Sexually transmitted infections 20010401

Trovafloxacin hepatotoxicity.

Digestive diseases and sciences 20010401

In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20010401

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.

Diagnostic microbiology and infectious disease 20010401

In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20010401

Penicillin-resistant Streptococcus pneumoniae endocarditis: a case report and review.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010315

Antimicrobial safety and tolerability: differences and dilemmas.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010315

Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.

Current medicinal chemistry 20010301

Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.

Saudi medical journal 20010301

Effects of fluoroquinolones on the locomotor activity in rats.

Archives of toxicology 20010301

Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila.

The Journal of antimicrobial chemotherapy 20010201

In vitro activity of new quinolones against Clostridium difficile.

The Journal of antimicrobial chemotherapy 20010201

Guidelines and critical pathways for severe hospital-acquired pneumonia.

Chest 20010201

Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.

Journal of clinical pharmacology 20010201

Pfizer accused of testing new drug without ethical approval.

BMJ (Clinical research ed.) 20010127

Nigerian government investigates Pfizer drug trial allegations.

Lancet (London, England) 20010113

Bactericidal assays for fluoroquinolones.

Methods in molecular biology (Clifton, N.J.) 20010101

In vitro development of resistance to three quinolones in Streptococcus pneumoniae.

Chemotherapy 20010101

Measurement of the bactericidal activity of fluoroquinolones against Streptococcus pneumoniae using the bactericidal index method.

International journal of antimicrobial agents 20010101

Antibiotic side effects.

The Medical clinics of North America 20010101

Multifocal Staphylococcus aureus infection originating from the sacroiliac joint in a patient with rheumatoid arthritis.

The Journal of rheumatology 20010101

Trovafloxacin-associated leukopenia.

The Annals of pharmacotherapy 20010101

Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.

Microbial drug resistance (Larchmont, N.Y.) 20010101

Telithromycin.

Drugs 20010101

In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.

Diagnostic microbiology and infectious disease 20010101

Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.

Diagnostic microbiology and infectious disease 20010101

Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae.

BMC microbiology 20010101

Serious liver injury. Leading reason for drug removals, restrictions.

FDA consumer 20010101

Experimental intravitreal application of trovafloxacin in rabbits.

Ophthalmic research 20010101

History of quinolones and their side effects.

Chemotherapy 20010101

Comparison of side effects of levofloxacin versus other fluoroquinolones.

Chemotherapy 20010101

Latest industry information on the safety profile of levofloxacin in Japan.

Chemotherapy 20010101

In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.

Chemotherapy 20010101

In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.

Diagnostic microbiology and infectious disease 20010101

In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.

Cardiovascular drugs and therapy 20010101

Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico.

Scandinavian journal of infectious diseases 20010101

Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.

Antimicrobial agents and chemotherapy 20001001

Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.

Antimicrobial agents and chemotherapy 20001001

In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.

Antimicrobial agents and chemotherapy 20000901

Effects of trovafloxacin on the IL-1-dependent activation of E-selectin in human endothelial cells in vitro.

Immunopharmacology 20000601

Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin.

Pharmacotherapy 20000501

Trovafloxacin-induced weakness due to a demyelinating polyneuropathy.

Southern medical journal 20000501

Trovafloxacin-induced acute hepatitis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20000201

Double-blind comparison of trovafloxacin and doxycycline in the treatment of uncomplicated Chlamydial urethritis and cervicitis. Trovafloxacin Chlamydial Urethritis/Cervicitis Study Group.

Sexually transmitted diseases 19991001

Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin.

Antimicrobial agents and chemotherapy 19990701

The 2-pyridone antibacterial agents: 8-position modifications.

Current pharmaceutical design 19990701

In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Antimicrobial agents and chemotherapy 19990501

Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19980601

In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.

The Journal of antimicrobial chemotherapy 19971201

In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.

The Journal of antimicrobial chemotherapy 19970601

Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.

Antimicrobial agents and chemotherapy 19970501

The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.

The Journal of antimicrobial chemotherapy 19970401

Trovafloxacin is active against Toxoplasma gondii.

Antimicrobial agents and chemotherapy 19960801

147059-72-1 | 1,8-Naphthyridine-3-carboxylic acid, 7-[(1α,5α,6α)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-

Product Description

Properties

Literature

Related Products

Featured Products